GSK3050002 (previously known as KANAb071) is an investigational monoclonal antibody that is an antagonist for human CCL20, a chemokine ligand that binds to the CCR6 receptor. The CCL20/CCR6 interaction is implicated in a range of autoimmune diseases. GSK3050002 was investigated in a Phase I safety and tolerability study (NCT01984047) in healthy volunteers, and is the first investigational antibody to enter clinical development from the collaboration established between GlaxoSmithKline (GSK) and Morphotek. GSK recently initiated a Phase 1 study (NCT02671188) in psoriatic arthritis patients.
GSK3050002 was developed from a non-humanized antibody originally discovered by KAN Research Institute, Inc., a subsidiary of Eisai Co., Ltd.
For more information about GSK3050002, please click here.
The information contained herein is investigational and is not intended to make claims of safety or efficacy prior to approval by the FDA or other regulatory authorities. There is no guarantee that the agents described or their uses will be approved by the FDA or other regulatory authorities.